

# NIH funding opportunities

19 Feb 2024 (#07)



**Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.**



See all Important Notices, Parent Announcements and Notice of Special Interest below

**Plan your application. Before starting your application attend**

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

**To prepare an application can take *4-18 months*.**

**From submission to receiving a Notice of Award can take *10 months***

## Important Notices

**[Workshop for Early Career Investigators in HIV](#)** The NIH Office of AIDS Research (OAR), along with other NIH institutes, centers, and offices (ICOs) with HIV research programs are hosting a virtual workshop. Participants will have the opportunity to Learn about the role of OAR and HIV research across NIH and network with fellow HIV researchers, exchange ideas, and meet possible collaborators among the next generation of HIV investigators. Audience: Early-stage investigators (ESI) are scientists within 10 years of earning their terminal degree who are applying for an independent grant. Event date: April 24, 2024. [Register for NIH OAR Workshop](#) .

**[NOT-OD-24-060 Request for Information \(RFI\) to inform development of the FY 2026-2030 NIH Strategic Plan for HIV and HIV-Related Research.](#)** Through this Request for Information (RFI), the Office of AIDS Research (OAR) in the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), National Institutes of Health (NIH), invites feedback from researchers, health care professionals, advocates and health advocacy organizations, scientific or professional organizations, federal/state/local government agencies, community, and other interested constituents on the development of the fiscal year (FY) 2026-2030 NIH Strategic Plan for HIV and HIV-Related Research (the Plan). The [Plan](#) guides the NIH investment, building on scientific progress and opportunities for advancing HIV/AIDS research toward an end to the pandemic.

**[NOT-OD-24-061 NIH Guidance on Marking Changes in Resubmission Applications.](#)** Effective May 25, 2024, this guidance replaces previous guidance on marking changes in [Resubmission applications](#). The use of markups such as bracketing, indenting, highlighting, bolding, italicizing, underlining, margin lines, change in typography, font, or font color, or any other type of markup should not be used to identify changes in Resubmission applications. Changes made to a Resubmission application should only be outlined in the Introduction attachment. The Introduction must include a summary of substantial additions, deletions, and changes to the application. It must also include a response to weaknesses raised in the Summary Statement. Introduction may not exceed one page.

[NOT-AG-23-079](#) Notice of Change to Key Dates Listed in [PAR-24-092](#), "Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)". This Notice informs potential applicants that the Key Dates information listed in the NOFO has changed. Only AIDS applications are accepted. The "Expiration Date:" was updated to January 08, 2027.

[NOT-AG-23-081](#) Notice of Change to Key Dates Listed in [PAR-24-091](#), "Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)". This Notice informs potential applicants that the Key Dates information listed in the NOFO has changed. Only AIDS applications are accepted. The "Expiration Date:" was updated to January 08, 2027.

[NOT-MH-24-175](#) Notice of Extension to [PA-21-199](#) Research on Autism Spectrum Disorders (R03 Clinical Trial Optional) and [PA-21-200](#) Research on Autism Spectrum Disorders (R21 Clinical Trial Optional). Due to the extension, the following application due date will be added: June 16, 2024, and October 16, 2024.

[NOT-MH-24-176](#) Notice of Extension to [PA-21-201](#) Research on Autism Spectrum Disorders (R01 Clinical Trial Optional). Additional two receipt dates, June 5, 2024, and October 5, 2024 were added.

[NOT-MH-24-185](#) Notice of Extension to [PAR-21-210](#), Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01). Additional two receipt dates, June 5, 2024, and October 5, 2024 were added.

[NOT-MH-24-186](#) Notice of Extension to [PAR-21-211](#), Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required). Additional two receipt dates, June 16, 2024, and October 16, 2024.

[NOT-AR-25-004](#) Notice of Intent to Publish a Funding Opportunity Announcement for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional). The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the National Institute of Neurological Disorders and Stroke (NINDS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and National Heart, Lung and Blood Institute (NHLBI), intend to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational, and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. Among the areas of research encouraged in this initiative are patient-oriented and synergistic pre-clinical research examining the mechanisms that underlie the effects of muscular dystrophies as well as research designed to improve the translation of existing knowledge of strategies for the prevention and treatment of muscular dystrophies. NIH intends to commit a total of \$4,800,000, for fiscal year 2025. Future year amounts will depend on annual appropriations. Applicants may request up to \$1,000,000 direct costs/year (exclusive of facilities and administrative costs of subcontractors with collaborating organizations) for up to five years. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

[NOT-AG-23-084](#) The National Institute on Aging (NIA) Caenorhabditis Interventions Testing Program(CITP) Announces Annual Call for Compounds to Test for Lifespan Extension in Caenorhabditis. This is not a Notice of Funding Opportunity (NOFO), but rather a solicitation of suggestions for compounds to be tested in the CITP. The deadline for receipt of proposals is May 1, 2024.

## Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates Expiration Date: May 8, 2023. **Modified Expiration Date: May 8, 2024**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

[NOT-CA-24-028](#) **Administrative Supplements for NCI Global Oncology Mentored Research.** The National Cancer Institute (NCI) encourages eligible grantees to apply for administrative supplements to support cancer research career development of early-stage Low- and Middle-Income Country (LMIC) investigators (ESLIs). The NCI Global Oncology Mentored Research Supplement initiative is designed to support high-quality mentored research experiences for ESLIs within the context of NCI extramural research projects. The overarching goal of this supplement is to strengthen the capacity of LMIC investigators to conduct high-quality independent and/or collaborative research in their home institutions thereby generating context-appropriate evidence to address the growing cancer problem in LMICs. Eligibility: Eligible activity codes for applications are limited to the following: R01, R35, R37, P01, P20, P50, U01, U19, U54, UH2, UH3, UG1, UG3 or UM1. No other grant or cooperative agreement mechanisms are eligible for this program. The budget should not exceed \$125,000 in total costs. The application budget is limited to 1 year only.

[NOT-CA-24-031](#) **Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research.** The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI/ML algorithms. Research supported by this NOSI is expected to provide support for analytical and/or clinical validation of recently developed digital health and AI/ML technologies. Investigators must carefully review the specific research interests of NIH Institutes and Centers (ICs) that are participating in this NOSI. This notice applies to due dates on or after April 05, 2024, and subsequent receipt dates through July 06, 2025.

[NOT-DE-24-011](#) **Determining the Tri-directional Relationship Among Oral Health, Nutrition, and Comprehensive Health.** The purpose of this NOSI is to support research to better understand the mechanisms of the tri-directional relationship among nutrition, systemic health, and oral, dental, and craniofacial (DOC) health and the development of nutritional interventions in the dental setting. This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through September 8, 2027.

## Notice of Funding Opportunity (NOFO)

1. [RFA-AG-25-005](#) **Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Primary Prevention Trials (U24 Clinical Trial Not Allowed).** This Notice of Funding Opportunity (NOFO) invites U24 Cooperative Agreement applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. The National Institute on Aging (NIA) is particularly interested in proposals that aim to advance equity for populations disproportionately impacted by AD/ADRD.

**Due dates:** June 15, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** NIA intends to commit \$8,000,000 in FY 2025 to fund one award. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

2. [RFA-MH-25-170](#) **BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional).** Guided by the goals established in [BRAIN 2025: A Scientific Vision](#) and reinforced by the [Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup](#), this Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human

brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This NOFO encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. For small projects that are primarily exploratory in nature or designed to generate pilot data in preparation for a larger study, applicants should consider [RFA-MH-25-171](#), the BRAIN Initiative Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science Exploratory/ Developmental Research (R21) NOFO.

**Due dates:** October 11, 2024; October 10, 2025; October 09, 2026. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** NIH BRAIN and partner components intend to commit an estimated total of \$3M in fiscal years 2025, 2026, 2027 to fund up to 8 new awards, each year, contingent upon annual appropriations. Application budgets are limited to \$300,000 in direct costs in any project year and need to reflect the actual needs of the proposed project. The maximum project period is 4 years.

<b>Faculty of Medicine and Health Sciences</b> <b>Research &amp; Internationalisation Development &amp; Support</b> <b>(RIDS) &amp; Grants Management Office (GMO)</b> 009 K <sup>th</sup> Floor, Teaching Block, Tygerberg Campus.	<b>Stellenbosch Campus</b> <b>Division for Research Development (DRD)</b> 2041 Krotoa Building, Ryneveld Street
<b>Enquiries:</b> <a href="mailto:cdevries@sun.ac.za">cdevries@sun.ac.za</a> / <a href="mailto:fmhsgmo@sun.ac.za">fmhsgmo@sun.ac.za</a>	<b>Enquiries:</b> <a href="mailto:research@sun.ac.za">research@sun.ac.za</a>
<b>Add “Interest in NIH opportunity” in the subject line. Add the notice number in the text of the email.</b>	